Durvalumab plus tremelimumab temporarily reduces QoL in resected renal cell carcinoma patients
Durvalumab plus tremelimumab temporarily reduces QoL in resected renal cell carcinoma patients
Induction ipilimumab plus nivolumab followed by chemoradiotherapy achieves high bladder preservation and survival in MIBC
Lutetium-177 PSMA-617 improves progression-free survival without worsening QoL in mHSPC
Patients with non-metastatic HSPC prefer ARPI-based therapy over androgen deprivation alone
Enzalutamide plus leuprolide achieves durable PSA suppression after treatment suspension
Cabozantinib shows clinical benefit in refractory GCT with over 40% disease control
Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab improves pathological and DFS outcomes in MIBC
Neoadjuvant cabozantinib plus nivolumab before cytoreductive nephrectomy shows promising responses in metastatic clear cell RCC
ASCO GU 2026: Updates in metastatic prostate cancer
ASCO GU 2026: Updates in localised prostate cancer
Post-orchiectomy miR-371 predicts recurrence in clinical stage I testicular germ cell tumours during active surveillance
Enfortumab vedotin and pembrolizumab improves EFS, OS, and pCR in muscle-invasive bladder cancer